{"id":"NCT02137226","sponsor":"Boehringer Ingelheim","briefTitle":"BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis","officialTitle":"Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-26","primaryCompletion":"2016-03-03","completion":"2016-10-18","firstPosted":"2014-05-13","resultsPosted":"2017-12-08","lastUpdate":"2018-01-19"},"enrollment":645,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"BI 695501","otherNames":[]},{"type":"DRUG","name":"US-licensed Humira®","otherNames":[]}],"arms":[{"label":"BI 695501","type":"EXPERIMENTAL"},{"label":"US-licensed Humira®","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nThe primary objective of this trial is to establish an equivalence in efficacy between BI 695501 and US-licensed Humira® in patients with active Rheumatoid arthritis based on a statistical comparison of the proportion of patients meeting American College of Rheumatology 20% (ACR20) response rate at Week 12 and ACR20 response rate at Week 24 between BI 695501 and US-licensed Humira®.\n\nSecondary Objectives:\n\nThe secondary objectives of this trial are to compare the efficacy, safety and immunogenicity of BI 695501 and US-licensed Humira® in patients with active RA including those undergoing the transition from US-licensed Humira® to BI 695501 after 24 weeks.","primaryOutcome":{"measure":"The Proportion of Patients Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"BI 695501","deltaMin":67,"sd":null},{"arm":"US-licensed Humira®","deltaMin":61.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":31},"locations":{"siteCount":138,"countries":["United States","Bulgaria","Chile","Estonia","Germany","Hungary","Malaysia","New Zealand","Poland","Russia","Serbia","South Korea","Spain","Thailand","Ukraine"]},"refs":{"pmids":["39551590","39120847","36065786","33263165","32363771","29514803"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":324},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}